MX2020006088A - Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos. - Google Patents
Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos.Info
- Publication number
- MX2020006088A MX2020006088A MX2020006088A MX2020006088A MX2020006088A MX 2020006088 A MX2020006088 A MX 2020006088A MX 2020006088 A MX2020006088 A MX 2020006088A MX 2020006088 A MX2020006088 A MX 2020006088A MX 2020006088 A MX2020006088 A MX 2020006088A
- Authority
- MX
- Mexico
- Prior art keywords
- rnai constructs
- pnpla3 expression
- inhibiting pnpla3
- inhibiting
- liver disease
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 101100244213 Homo sapiens PNPLA3 gene Proteins 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01051—1-Acylglycerol-3-phosphate O-acyltransferase (2.3.1.51)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597841P | 2017-12-12 | 2017-12-12 | |
| PCT/US2018/065275 WO2019118638A2 (en) | 2017-12-12 | 2018-12-12 | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006088A true MX2020006088A (es) | 2020-08-24 |
Family
ID=65139138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006088A MX2020006088A (es) | 2017-12-12 | 2018-12-12 | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos. |
| MX2025010269A MX2025010269A (es) | 2017-12-12 | 2020-07-13 | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010269A MX2025010269A (es) | 2017-12-12 | 2020-07-13 | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20210139912A1 (https=) |
| EP (1) | EP3724337A2 (https=) |
| JP (3) | JP2021506238A (https=) |
| KR (1) | KR20200097299A (https=) |
| CN (1) | CN111699257A (https=) |
| AR (1) | AR113490A1 (https=) |
| AU (2) | AU2018386089A1 (https=) |
| BR (1) | BR112020011686A2 (https=) |
| CA (1) | CA3084133A1 (https=) |
| CL (2) | CL2020001543A1 (https=) |
| CO (1) | CO2020008485A2 (https=) |
| CR (1) | CR20200304A (https=) |
| EA (1) | EA202091437A1 (https=) |
| IL (1) | IL275029A (https=) |
| JO (1) | JOP20200142A1 (https=) |
| MX (2) | MX2020006088A (https=) |
| PE (1) | PE20210633A1 (https=) |
| PH (1) | PH12020550833A1 (https=) |
| SG (1) | SG11202005257UA (https=) |
| TW (1) | TW201938792A (https=) |
| UY (1) | UY38003A (https=) |
| WO (1) | WO2019118638A2 (https=) |
| ZA (1) | ZA202003982B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| EA201792263A1 (ru) | 2015-04-13 | 2018-08-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| IL277889B2 (en) | 2018-04-12 | 2025-01-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods of using them |
| EP3790596A4 (en) | 2018-05-11 | 2022-04-06 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE |
| TWI856973B (zh) | 2018-09-19 | 2024-10-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| CN113166761B (zh) * | 2018-12-10 | 2025-09-09 | 美国安进公司 | 用于抑制pnpla3表达的rnai构建体 |
| EP4045062A1 (en) * | 2019-10-14 | 2022-08-24 | Astrazeneca AB | Modulators of pnpla3 expression |
| US20230078200A1 (en) * | 2019-12-09 | 2023-03-16 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
| BR112022011412A2 (pt) | 2019-12-16 | 2022-08-30 | Alnylam Pharmaceuticals Inc | Composições de irna de domínio de fosfolipase semelhante à patatina contendo proteína 3 (pnpla3) e métodos de uso das mesmas |
| TW202138559A (zh) * | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法 |
| EP4096396A1 (en) | 2020-01-28 | 2022-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| TW202202153A (zh) * | 2020-03-26 | 2022-01-16 | 美商艾羅海德製藥公司 | 用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法 |
| KR102812602B1 (ko) | 2020-08-05 | 2025-05-28 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| US12084662B2 (en) | 2021-04-14 | 2024-09-10 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating PNPLA3 expression |
| AU2022339846A1 (en) * | 2021-09-01 | 2024-03-14 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| JP2025542119A (ja) * | 2022-12-07 | 2025-12-25 | シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド | パタチン様ホスホリパーゼドメイン含有３（ｐｎｐｌａ３）の発現を阻害するための組成物及び方法 |
| CN117904108A (zh) * | 2022-12-12 | 2024-04-19 | 北京福元医药股份有限公司 | 用于抑制pnpla3基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
| WO2024182446A2 (en) * | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| DE69233501T2 (de) | 1991-11-22 | 2006-02-23 | Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara | Kombinatorische Strategien für die Polymersynthese |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| ATE285477T1 (de) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| DK1620544T3 (en) | 2003-04-17 | 2019-01-14 | Alnylam Pharmaceuticals Inc | MODIFIED iRNA AGENTS |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| US20100056384A1 (en) * | 2008-09-04 | 2010-03-04 | Board Of Regents, The University Of Texas System | Sequence Variations in PNPLA3 Associated with Hepatic Steatosis |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP3564374A1 (en) | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| WO2016130806A2 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| EP3350328A1 (en) * | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
| US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11597927B2 (en) * | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN113166761B (zh) * | 2018-12-10 | 2025-09-09 | 美国安进公司 | 用于抑制pnpla3表达的rnai构建体 |
-
2018
- 2018-12-11 AR ARP180103612A patent/AR113490A1/es unknown
- 2018-12-11 UY UY0001038003A patent/UY38003A/es not_active Application Discontinuation
- 2018-12-12 CA CA3084133A patent/CA3084133A1/en active Pending
- 2018-12-12 KR KR1020207019521A patent/KR20200097299A/ko not_active Ceased
- 2018-12-12 EA EA202091437A patent/EA202091437A1/ru unknown
- 2018-12-12 PE PE2020000745A patent/PE20210633A1/es unknown
- 2018-12-12 TW TW107144746A patent/TW201938792A/zh unknown
- 2018-12-12 CR CR20200304A patent/CR20200304A/es unknown
- 2018-12-12 AU AU2018386089A patent/AU2018386089A1/en not_active Abandoned
- 2018-12-12 WO PCT/US2018/065275 patent/WO2019118638A2/en not_active Ceased
- 2018-12-12 BR BR112020011686-6A patent/BR112020011686A2/pt unknown
- 2018-12-12 SG SG11202005257UA patent/SG11202005257UA/en unknown
- 2018-12-12 MX MX2020006088A patent/MX2020006088A/es unknown
- 2018-12-12 EP EP18836995.3A patent/EP3724337A2/en active Pending
- 2018-12-12 CN CN201880088895.5A patent/CN111699257A/zh active Pending
- 2018-12-12 JP JP2020530513A patent/JP2021506238A/ja active Pending
- 2018-12-12 US US16/771,907 patent/US20210139912A1/en active Pending
-
2020
- 2020-06-01 IL IL275029A patent/IL275029A/en unknown
- 2020-06-05 PH PH12020550833A patent/PH12020550833A1/en unknown
- 2020-06-07 JO JOP/2020/0142A patent/JOP20200142A1/ar unknown
- 2020-06-10 CL CL2020001543A patent/CL2020001543A1/es unknown
- 2020-06-30 ZA ZA2020/03982A patent/ZA202003982B/en unknown
- 2020-07-10 CO CONC2020/0008485A patent/CO2020008485A2/es unknown
- 2020-07-13 MX MX2025010269A patent/MX2025010269A/es unknown
-
2023
- 2023-08-10 CL CL2023002358A patent/CL2023002358A1/es unknown
- 2023-10-26 JP JP2023183884A patent/JP2024012386A/ja active Pending
-
2025
- 2025-01-17 US US19/028,462 patent/US20250154512A1/en active Pending
- 2025-04-30 AU AU2025203098A patent/AU2025203098A1/en active Pending
- 2025-09-12 JP JP2025152531A patent/JP2025186376A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY38003A (es) | 2019-06-28 |
| CN111699257A (zh) | 2020-09-22 |
| EP3724337A2 (en) | 2020-10-21 |
| AU2025203098A9 (en) | 2026-03-05 |
| JP2025186376A (ja) | 2025-12-23 |
| JP2024012386A (ja) | 2024-01-30 |
| CO2020008485A2 (es) | 2020-07-31 |
| PE20210633A1 (es) | 2021-03-23 |
| BR112020011686A2 (pt) | 2020-11-24 |
| US20210139912A1 (en) | 2021-05-13 |
| AU2025203098A1 (en) | 2025-05-22 |
| JP2021506238A (ja) | 2021-02-22 |
| EA202091437A1 (ru) | 2020-12-29 |
| CR20200304A (es) | 2020-09-04 |
| KR20200097299A (ko) | 2020-08-18 |
| PH12020550833A1 (en) | 2021-07-05 |
| IL275029A (en) | 2020-07-30 |
| MX2025010269A (es) | 2025-10-01 |
| US20250154512A1 (en) | 2025-05-15 |
| CL2020001543A1 (es) | 2020-08-28 |
| AR113490A1 (es) | 2020-05-06 |
| AU2018386089A1 (en) | 2020-06-18 |
| SG11202005257UA (en) | 2020-07-29 |
| TW201938792A (zh) | 2019-10-01 |
| JOP20200142A1 (ar) | 2022-10-30 |
| ZA202003982B (en) | 2021-07-28 |
| CA3084133A1 (en) | 2019-06-20 |
| WO2019118638A2 (en) | 2019-06-20 |
| CL2023002358A1 (es) | 2024-02-23 |
| WO2019118638A3 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025010269A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos | |
| PH12021551326A1 (en) | Rnai constructs for inhibiting pnpla3 expression | |
| AU2019268063A1 (en) | Compositions for modulating sod-1 expression | |
| JOP20230030A1 (ar) | بنيات RNAi وطرق لتثبيط التعبير عن MARC1 | |
| MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
| JO3558B1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
| MX2022015169A (es) | Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos. | |
| PH12017501925A1 (en) | Pyrazole compounds and method for making and using the compounds | |
| MX2026000159A (es) | Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas | |
| MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
| PH12016501441B1 (en) | Chimeric alkaline phosphatase-like proteins | |
| MX2024009873A (es) | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. | |
| EA201692473A1 (ru) | Способы получения замещенных нуклеотидных аналогов | |
| ZA201901168B (en) | Novel compounds for treating parasitic disease | |
| MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
| MX2024004913A (es) | Constructos de arni para inhibir la expresion de gpam y metodos de uso de los mismos. |